Brief: Nanexa Develops Long-Acting Formulation
15/09/2022 13:21
Sept 15 (Reuters) - Nanexa AB NANEXA.ST :
* ANNOUNCED TODAY THAT IT HAS DECIDED TO DEVELOP A
LONG-ACTING
FORMULATION OF LIRAGLUTIDE WITH PHARMASHELL® FOR TREATMENT OF
TYPE 2 DIABETES
* NEX-22 WILL BE COMPANY'S THIRD PROPRIETARY PRODUCT
DEVELOPMENT
PROJECT
* WORK ON FORMULATION OF NEX-22 HAS STARTED IN 2022 AND WILL
CONTINUE WITH PRECLINICAL DEVELOPMENT IN COMING QUARTERS WITH
GOAL OF STARTING CLINICAL TRIALS IN 2023
Source text for Eikon: ID:nMFN3hZsR2
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))